 Home > Medical News > Medical Research Articles > Nuocheng Jianhua announced the latest clinical data of the pan-FGFR inhibitor gunagratinib at the 2021 American Society of Clinical Oncology (ASCO) annual meeting

Nuocheng Jianhua announced the latest clinical data of the pan-FGFR inhibitor gunagratinib at the 2021 American Society of Clinical Oncology (ASCO) annual meeting

 Last Update: 2021-06-30
 Source: Internet
 Author: User

Tags

phase change material

new bowling balls

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Biomedical high-tech company Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) today announced the latest clinical data of the pan-FGFR inhibitor ICP-192 (gunagratinib) at the 2021 American Society of Clinical Oncology (ASCO) annual meeting
.

This is the first time that gunagratinib has presented clinical data at an international academic conference, showing good safety and tolerability

Selected study: a highly selective irreversible FGFR inhibitor ICP-192 (gunagratinib) for the phase I clinical results of patients with advanced solid tumors with abnormal FGFR gene (abstract code: 4092)
.

ICP-192 (gunagratinib) independently developed by Nuocheng Jianhua is a new and highly selective pan-FGFR (fibroblast growth factor receptor) inhibitor, which can irreversibly inhibit FGFR activity through covalent binding, and can also overcome the first Acquired resistance of the first generation of reversible FGFR inhibitors
.

Gunagratinib is currently in clinical phase I/II, and the safety and tolerability of this inhibitor in patients with advanced solid tumors as well as pharmacokinetic/pharmacodynamic (PK/PD) characteristics have been evaluated, and RECIST1 has been adopted.
1 Criteria to evaluate the initial efficacy in patients with FGF/FGFR gene mutations
.

As of February 2021, a total of 30 patients have been treated with gunagratinib
.

The safety and tolerance are good, and the maximum tolerated dose (MTD) has not been reached

Professor Guo Ye, deputy director of the Department of Cancer Medicine and Director of the Phase I Clinical Center of Shanghai Dongfang Hospital, said: “In patients with advanced solid tumors, gunagratinib is safe and well tolerated
.

There are many FGF/FGFR gene mutations in the treatment of cholangiocarcinoma.

The 2021 ASCO Annual Meeting will be held online from June 4 to 8, 2021
.

The ASCO annual meeting is an important and authoritative academic exchange event in the global oncology field, which will showcase the current international cutting-edge clinical oncology scientific research results and tumor treatment technologies

About Nuocheng Jianhua

Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) is a commercialized biomedical high-tech company, focusing on the development of a class of new drugs in the treatment of malignant tumors and autoimmune diseases, suitable for the high incidence of lymphoma in Chinese patients , Liver cancer, cholangiocarcinoma, urothelial cancer and other malignant tumors and autoimmune diseases
.

Several new drug products are currently in commercialization, clinical and pre-clinical research and development stages

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.